A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

By Karen Roman Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial ...

Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

A five-year-old boy who received the world's most expensive drug as a baby has made "incredible progress" and can walk ...

For many East Tennessee kids, running and playing comes as naturally to them as breathing. For Jerrick Johnson and his mother ...

The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across ...

A 10-month-old baby who sparked nationwide headlines after receiving a first-of-its kind gene-editing treatment was released from the hospital this week.

Results from the largest cohort of children who received a gene therapy for a rare immunodeficiency condition have shown the long-term safety and efficacy of the curative treatment, in a study led by ...

The Gene Therapy R&D market presents robust opportunities, driven by clinical advancements in CAR-T therapies and a strong pipeline, particularly for cancer and rare diseases. Despite challenges from ...

Relief from Parkinson's symptoms may one day be an injection away. June 22, 2007 &#151; -- Sufferers of Parkinson's disease, from Michael J. Fox to Muhammad Ali, may benefit from a promising but ...